Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

And, like Lilly, Novo is also testing its semaglutide in ... Reuters reported at the time, just a few months after Zepbound’s ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the ... positive airway pressure (PAP) therapy — like what’s known as a CPAP machine — the ...

UnitedHealthcare taught us ways to deny claims: Former employee “Too often, OSA is brushed off as ‘just snoring ... including new options like Zepbound. We hope this will spark more ...